BioXcel Therapeutics Inc at UBS Global Healthcare Conference Transcript
Good morning, everyone, and thanks for coming to the UBS Global Healthcare Conference. I'm Colin Bristow, one of the biotech analysts here. And it's my pleasure to have the BioXcel team with us. On my right, I have Vimal Mehta, Founder and CEO of BioXcel. Also from the team, we have Matt Wiley and Vince O'Neill.
Vimal, I know you have some opening statements, and congratulations on the recent approval launch. So I'll let you kick it off.
Thank you, Colin, good morning, everyone. BioXcel Therapeutics is a biopharmaceutical company, developing innovative medicines in neuroscience and immuno-oncology using AI-based approach. Our 2 lead products are BXCL501, which is for acute treatment of agitation and BXCL701, which is an innate immunity activator. So those are our 2 lead products. We are very excited that this has been a very transformative year for the company, considering that we got the FDA
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |